Antifungal susceptibility testing of clinical isolates of fluconazole-resistant Candida spp. and itraconazole-resistant Aspergillus funmigates to posaconazole

Abstract

Abstract:

Objective To determine the in vitro susceptibility of fluconazole (FLU)-resistant Candida spp. and itraconazole (ITC)-resistant Aspergillus spp. to posaconazole (POS).Methods The MICs of FLU, ITC, voriconazole (VRC) and POS were determined according to CLSI M27-A3 and M38-A2 methods in eleven isolates of Candida spp. and three isolates of Aspergillus spp.Results MICs of FLU, ITC, VRC and POS against FLU-resistant Candida spp. were 64 μg/mL, 0.5~16 μg/mL, 0.25~2 μg/mL and 0.125~1 μg/mL. And MICs of ITC, VRC and POS against ITC-resistant Aspergillus spp. were >16 μg/mL, 1~2 μg/mL and 0.25~0.5 μg/mL.Conclusion POS is effective to FLU-resistant Candida spp. and ITC-resistant Aspergillus spp. in vitro.

Key words: drug resistance, Candida, Aspergillus fumigatus, posaconazole

CLC Number:

R978.5

WANG Xue-jie, WAN Zhe, LI Ruo-yu, LIU Wei. Antifungal susceptibility testing of clinical isolates of fluconazole-resistant Candida spp. and itraconazole-resistant Aspergillus funmigates to posaconazole[J]. Chinese Journal of Mycology, 2014, 9(2): 75-78.

References

[1] Silva S, Negri M, Henriques M, et al.Candida glabrata,Candida parapsilosis and Candida tropicalis:biology, epidemiology, pathogenicity and antifungal resistance[J]. FEMS Microbiol Rev, 2012, 36(2): 288-305.
[2] 陈翠珠, 徐英春, 王澎, 等. 1557株酵母菌的鉴定及其药敏试验分析[J]. 中国真菌学杂志,2006, 1(3): 134-138.
[3] Rodloff C, Koch D, Schaumann R. Epidemiology and antifungal resistance in invasive candidiasis[J]. Eur J Med Res, 2011, 16(4): 187-195.
[4] Wang H, Xiao M, Chen SC, et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol, 2012, 50(12): 3952-3959.
[5] Pfaller MA, Diekema DJ, Ghannoum MA, et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods[J]. J Clin Microbiol, 2009, 47(10): 3142-3146.
[6] Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities[J]. Trends Microbiol, 2010, 18(5): 195-204.
[7] Warrilow AG, Melo N, Martel CM, et al. Expression, purification, and characterization of Aspergillus fumigates sterol 14-alpha demethylase (CYP51) isoenzymes A and B[J]. Antimicrob A gents Chemother, 2010, 54(10): 4225-4234.
[8] Nagappan V, Deresinski S. Reviews of anti-infective agents: Posaconazole: a broad-spectrum triazole antifungal agent[J]. Clin Infect Dis, 2007, 45(12): 1610-1617.
[9] Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts[S]. Approved standard-Third edition M27-A3. CLSI, Wayne, PA, 2008.
[10] Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi[S]. Approved standard-Second edition M38-A2. CLSI, Wayne, PA, 2008.
[11] Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin[J]. Journal of clinical microbiology, 2011, 49(2): 624-629.
[12] Verweij PE, Howard SJ, Melchers WJ, et al. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints[J]. Drug Resist Update, 2009, 12(6): 141-147.
[13] Mishra NN, Prasad T, Sharma N, et al. Pathogenicity and drug resistance in Candida albicans and other yeast species. A review[J]. Acta Microbiol Immunol Hung, 2007, 54(3): 201-235.
[14] Mayr A, Lass-Fl?rl C. Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature[J]. Eur J Med Res, 2011, 16(4): 153-157.
[15] Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections[J]. Clin Epidemiol, 2011, 3(1):175-191.
[16] 芦现杰, 郑玉果, 周斌. 真菌对唑类药物耐药机制研究进展[J]. 世界临床药物, 2012, 33(6): 363-368.
[17] 索桂英, 付萍. 白念珠菌氟康哇耐药机制的研究进展[J]. 皮肤病与性病, 2013, 5(2): 90-94.
[18] 孙毅, 刘伟, 陈伟, 等. 对唑类药物交叉耐药的烟曲霉临床分离株耐药机制的初步探讨[J]. 中华皮肤科杂志, 2011, 44(4): 244-248.
[19] Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent[J]. Clin Ther,2007, 29(9): 1862-1886.
[20] Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease[J]. N Engl J Med, 2007, 356(4): 335-347.
[21] Xiao L, Madison V, Chau AS, et al. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding[J]. Antimicrob Agents Chemother,2004,48:568-574.